Editing Imatinib (section)

===Chronic myelogenous leukemia===
The U.S. [[Food and Drug Administration]] (FDA) has approved imatinib as first-line treatment for [[Philadelphia chromosome]]-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed.<ref name="FDA">{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf |title=FDA Highlights and Prescribing Information for Gleevec(imatinib mesylate) |url-status=live |archive-url=https://web.archive.org/web/20140913120652/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf |archive-date=13 September 2014 }}</ref>

Due in part to the development of imatinib and related drugs, the five-year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009,<ref>{{cite web |url=http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics |title=Leukemia – Chronic Myeloid – CML: Statistics &#124; Cancer.Net |url-status=live |archive-url=https://web.archive.org/web/20141112155938/http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics |archive-date=12 November 2014 |date=26 June 2012}}</ref> to 70% in 2016.<ref>{{cite web |title=Cancer Stat Facts: Leukemia – Chronic Myeloid Leukemia (CML) |url=https://seer.cancer.gov/statfacts/html/cmyl.html |website=Cancer.gov |access-date=17 April 2020 |archive-date=1 February 2020 |archive-url=https://web.archive.org/web/20200201203304/https://seer.cancer.gov/statfacts/html/cmyl.html |url-status=live }}</ref> By 2023, the five year survival rate for people with chronic myeloid leukemia had risen to 90%.<ref>{{cite web |url=https://cancer.ca/en/cancer-information/cancer-types/chronic-myeloid-leukemia-cml/prognosis-and-survival/survival-statistics#:~:text=The%205%2Dyear%20relative%20survival,sex%20in%20the%20general%20population | title=Survival statistics for chronic myeloid leukemia | date=September 2022 | access-date=13 December 2023 | archive-date=13 December 2023 | archive-url=https://web.archive.org/web/20231213065443/https://cancer.ca/en/cancer-information/cancer-types/chronic-myeloid-leukemia-cml/prognosis-and-survival/survival-statistics#:~:text=The%205%2Dyear%20relative%20survival,sex%20in%20the%20general%20population | url-status=live }}</ref> Starting from 2011, it became clear that CML patients who continue to respond to imatinib have the same or almost the same life expectancy as the general population.<ref>{{cite journal |vauthors=Gambacorti-Passerini C, Antolini L, Mahon FX, et al. |title=Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib |journal=J. Natl. Cancer Inst. |volume=103 |issue=7 |pages=553–561|date=March 2011 |doi=10.1093/jnci/djr060  |pmid=21422402 |doi-access=free}}</ref>